shuaiDr. Gao received his PhD at University of Toledo working in Dr. Lirim Shemshedini's lab. He was focusing on study of targeting soluble guanylyl cyclase alpha-1 (sGCa1) using peptide in the prostate cancer. At Dr. Balk’s lab, Dr. Gao researched the mechanism of repressive function of androgen receptor (AR) in prostate cancer. It has been shown that AR suppresses the expression of genes mediating DNA synthesis and cell cycle progression, and this suppression is released in CRPC. Thus, it is crucial to block the derepression during the CRPC treatment. Currently, Dr. Gao is completing his postdoc under Dr. Changmeng Cai at the University of Massachusetts.


  1. Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 Mar 2. [Epub ahead of print]PMID: 26936914

  2. Chen E, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RT, Kantoff P, Montgomery B, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors (2015). Clin Cancer Res.

  3. Gao, S. , Hsieh, C-L. , Jun Zhou. , Shemshedini, L. (2013) Zinc Finger 280B Regulates sGCα1 and p53 in Prostate Cancer Cells. PLoS One 8(11):e78766

  4. Gao, S. * , Hsieh, C-L. *, Bhansali, M., Kannan, A., Shemshedini, L. (2013) A Peptide Against Soluble Guanylyl Cyclase a1: A New Approach to Treating Prostate Cancer. PLoS One 8(5):e64189

  5. Cai, C.*, Hsieh, C-L.*, Gao, S.*, Kannan, A., Bhansali, M., Govardhan, K., Dutta, R., Shemshedini, L. (2012) Soluble Guanylyl Cyclase a1 and p53 Cytoplasmic Sequestration and Down-Regulation in Prostate Cancer. Mol. Endocr. 26(2):292-307

* authors contributed equally